For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 0 | - | ||
| Research and development | 142,015 | 171,244 | ||
| General and administrative | 86,501 | 101,961 | ||
| Restructuring | 3,231 | - | ||
| Total operating expenses | 231,747 | 273,205 | ||
| Loss from operations | -231,747 | -273,205 | ||
| Interest expense | 1,891 | 1,886 | ||
| Interest and other income, net | 3,218 | 8,267 | ||
| Accretion of discount on investments, net | 7,297 | 8,078 | ||
| Net loss | -223,123 | -258,746 | ||
| Basic EPS | -2.01 | -2.73 | ||
| Diluted EPS | -2.01 | -2.73 | ||
| Basic Average Shares | 111,123,770 | 94,807,773 | ||
| Diluted Average Shares | 111,123,770 | 94,807,773 | ||
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)